Epitalon vs TA-65 compares two products sold to “turn on” telomerase, the enzyme that rebuilds telomeres, the protective caps on chromosomes that shorten with age. In brief: TA-65, an oral supplement from the Astragalus root, has a few small human trials, including one 117-person placebo-controlled study in which the low dose lengthened telomeres, all funded or co-authored by its maker.[8] Epitalon, a synthetic peptide, lengthened telomeres in cell studies, but FDA found no clinical studies of its safety.[2][1] Neither has been shown to extend human lifespan.
Epitalon vs TA-65 at a glance
| Epitalon | TA-65 | |
|---|---|---|
| What it is | Synthetic 4-amino-acid peptide (Ala-Glu-Asp-Gly)[1] | Small molecule purified from Astragalus membranaceus root[9] |
| Origin | Khavinson group, St. Petersburg, Russia[5] | Screening of traditional Chinese medicine extracts[8] |
| Typical route | Injection or under the tongue | Oral capsules |
| Telomere evidence | Human cell lines[2][3] | One randomized human trial[8] |
| Other human data | Russian studies, mostly of the related extract epithalamin[1] | Small trials in metabolic syndrome and macular degeneration[10][11] |
| US status | Unapproved drug; compounding under review[1] | Dietary supplement[8] |
How each one works
Both are pitched as telomerase activators.
Epitalon was designed from the amino-acid makeup of epithalamin, an extract of cow pineal glands. In a 2003 Russian study it switched on telomerase and lengthened telomeres in human lung cells.[2] A 2025 independent study at Brunel University London confirmed telomere lengthening in normal human cells, but also found that breast cancer cells lengthened their telomeres through a different pathway called ALT.[3]
TA-65 was found by screening plant extracts used in traditional Chinese medicine.[8] In mouse cells it lengthened short telomeres only when telomerase was present, supporting a telomerase-based mechanism.[9]
Evidence quality: the human studies
TA-65
- Randomized telomere trial (2016): 117 relatively healthy adults aged 53 to 87 took a low dose, a high dose or placebo for a year. The low-dose group gained about 530 base pairs of telomere length while the placebo group lost about 290; the high dose showed only a non-significant trend.[8] Two authors were employees of the maker, T.A. Sciences, and the others consulted for it or were funded by it.[8]
- Commercial program (2011): in people taking TA-65 alongside a supplement pack and lab monitoring, average telomere length did not increase, though the share of very short telomeres fell. There was no control group.[7]
- Metabolic syndrome (2018): a 40-person crossover trial reported higher HDL cholesterol and lower waist size and inflammation markers during the TA-65 phase.[10]
- Macular degeneration (2016): a 38-person pilot reported better retinal function with TA-65 than placebo at one year; one of its two authors also consulted for the maker, according to the 2016 trial disclosures.[11][8]
Epitalon
Most human research used epithalamin, the cow pineal extract, not synthetic epitalon, and FDA treats them as different substances.[1] Russian reports linked epithalamin to lower mortality in older adults followed for years.[4] An Alzheimer’s research foundation review noted that these studies come from one network and have not been independently confirmed.[5] For epitalon itself, FDA found only small studies, including two sublingual studies of melatonin markers in night-shift workers, and no clinical safety studies.[1]
Animal results
- Epitalon in mice: no change in average lifespan, a 12.3% longer maximum lifespan and less leukemia in one strain of female mice.[6] FDA criticized such studies for using single fixed doses and female mice only.[1]
- TA-65 in mice: in female mice fed TA-65, glucose tolerance, bone density and skin improved without a significant rise in overall cancer.[9]
- TA-65 in birds: in wild house sparrow chicks, TA-65 did not lengthen telomeres and, in one year, chicks lost more telomere length than controls.[12]
Side effects and the cancer question
Most cancers depend on telomerase to keep dividing, so switching it on carries a theoretical risk. FDA noted this for epitalon and found no standard two-year cancer studies.[1] The 2025 UK cell study showing cancer cells lengthening telomeres after epitalon exposure adds to that uncertainty.[3]
For TA-65, the 2011 program reported no adverse events attributed to it,[7] and the mouse study found no significant rise in cancer,[9] but long-term human cancer data do not exist for either product.
Product quality is another issue for epitalon: Belgian authorities identified it in illegal pharmaceutical preparations.[16]
Legal status and access
- TA-65 is sold in the US as a dietary supplement.[8] Supplements do not need FDA approval or proof of benefit before sale; see our guide to peptide supplements under DSHEA.
- Epitalon is not approved. FDA removed it from its compounding safety-risk list in April 2026 after the nomination was withdrawn, which is not an approval.[14] In July 2026, FDA advisers voted to recommend allowing compounding for insomnia, overriding FDA staff, who had advised against it; FDA had not issued a final decision as of October 2026.[1][13]
- Sport: neither is named on WADA’s 2026 list. As an unapproved substance, epitalon likely falls under the S0 category, which is banned at all times.[15]
Who might consider which? Questions for a clinician
- What would I expect to gain, and how would we measure it beyond a telomere test?
- Do I have a personal or family history of cancer?
- Am I taking other supplements or medicines that could interact?
- Is there an evidence-based step, such as exercise, sleep, blood pressure or blood sugar control, that would do more for healthy aging?
The verdict
TA-65 has slightly better human evidence, but it is small, mostly industry-linked and inconsistent. Epitalon’s telomere effects are confined to cells and animals, with human studies from one research network and no safety trials. Both carry an unresolved theoretical cancer question. Read more in our Khavinson peptide bioregulators guide, peptides vs exosomes, thymosin alpha-1 vs LL-37 and the longevity peptides hub.
This is general information, not medical advice.
